TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
COSMO Pharmaceuticals N.V. ( (CH:COPN) ) just unveiled an announcement.
Cosmo Pharmaceuticals reported strong financial results for the first half of 2025, leading to an increase in EBITDA guidance for the full year by EUR 4.5 million. The company experienced significant growth in recurring revenues, particularly from its GI Genius™ and Winlevi® products, and maintained a solid balance sheet. This performance aligns with Cosmo’s ‘Vision 2030’ strategy, emphasizing growth in AI-driven healthcare and specialty pharmaceuticals. The company anticipates continued momentum in the second half of 2025, with expectations of sustained growth in its key sectors, including MedTech AI and dermatology, which are driven by unmet clinical needs.
The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF133.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.
More about COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V. is a life-science company specializing in MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). The company designs and manufactures advanced solutions to meet critical medical needs, improving the standard of care globally. Founded in 1997 and headquartered in Dublin, Ireland, Cosmo operates with offices in the USA and Italy, focusing on innovations at the intersection of science and technology.
Average Trading Volume: 24,321
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.03B
Find detailed analytics on COPN stock on TipRanks’ Stock Analysis page.